




claim 1.

3. A mixture of compound I(a) and compound I(b), according to claim 2.
4. A mixture of compound I(c) and compound I(d), according to claim 2.
5. A compound mixture of, according to claim 3, wherein said mixture is racemic.
6. A compound mixture of, according to claim 4, wherein said mixture is racemic.
7. The compound I(a) and the compound I(b), according to claim 3, are each pure enantiomers.
8. The compound I(c) and the compound I(d), according to claim 4, are each pure enantiomers.
9. A compound according to claim 1 wherein **X** is H and **W** is OH; or **X** and **W** form a carbonyl group.
10. A compound according to claim 9 wherein **X** and **W** form a carbonyl group.
11. A compound according to claim 1 wherein ring **A** is a benzene ring, as represented by the formula I':



wherein X, R¹, W, Y, R³, and R⁴ are as defined in claim 1, with the provisos indicated in claim 1.

12. A compound according to claim 1 wherein ring A is a five-membered ring containing a sulfur atom, as represented by the formulae I'' and I''':



wherein R¹, X, W, Y, R³, and R⁴ are as defined in claim 1, without the provisos indicated in claim 1.

13. A compound according to claim 1, wherein R¹ is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl; or -C(O)R² wherein R² is lower alkyl, aryloxy or benzyloxy.

14. A compound according to claim 13, wherein R¹ is H, halo or C₁₋₄ alkyl.


15. A compound according to claim 14, wherein R¹ is H, fluoro or methyl.

16. A compound according to claim 15, wherein R¹ is H or methyl.

17. A compound according to claim 1, wherein **Y** is phenyl optionally mono- or di-substituted with **R**⁵ or C(O)**R**⁶, wherein **R**⁵ is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and **R**⁶ is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S; or **Y** is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with **R**⁵ or C(O)**R**⁶, wherein **R**⁵ and **R**⁶ are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4- to 6-membered ring optionally containing a heteroatom selected from N, O and S.

18. A compound according to claim 17, wherein **Y** is naphthyl, CH=CH-phenyl, C(CH₃)=CH-phenyl or phenyl, wherein the phenyl ring is optionally mono- or di-substituted at the 3, 4, or 5 position with **R**⁵, wherein **R**⁵ is halo, C₁₋₄ alkyl, hydroxy, CF₃ or NHC(O)-(lower alkyl).

19. A compound according to claim 18, wherein **Y** is phenyl optionally substituted with: 3,4-Cl; 3-F,4-Cl; 3-Cl,4-F; 3,4-Br; 3-F,4-CH₃; 3,4-CH₃; 3-CF₃, NHC(O)-





20. A compound according to claim 19, wherein **Y** is phenyl optionally substituted with: 3,4-Cl and 3,4-Br.


21. A compound according to claim 1, wherein **R**³ is selected from the group consisting of:

cyclohexyl; C₁₋₆ alkyl; C₁₋₆ thioalkyl; (C₁₋₆ alkyl)phenyl wherein the phenyl ring is optionally substituted with:

lower alkyl, CF₃, halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C₁₋₆ thioalkyl,


 ; and
 

C₁₋₆ alkyl; C₁₋₆ thioalkyl;




lower alkyl, lower cycloalkyl, haloalkyl (e.g. CF₃), halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C₁₋₆ thioalkyl, C₁₋₆ alkylsulfonyl, NHC(O)-lower alkyl, NHC(O)-aryl, NHC(O)-O-lower alkyl, NHC(O)O-aryl, aryl, aryloxy, hydroxy, nitro, amino, or Het, said Het optionally mono- or di-substituted with lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile, trifluoromethyl, C(O)R⁶ wherein

R^6 is as defined above;

said lower cycloalkyl, aryl, lower aralkyl or Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S; and















R^5 is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl,

25. A compound selected from the group consisting of: compounds having the following formula:






























, wherein R^{4A} , R^1 , R^5 and R^3 are as defined as follows:
















Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$
1002	Na	--	3,4-Cl	
1003	Na	--	4-Cl	
1004	Na	--	4-Cl	
1005	Na	--	4-Cl	
1006	Na	--	4-Cl	
















Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1007	Na	--	4-Cl	
1008	Na	--	4- <i>i</i> Pr	
1009	Na	--	4-Cl	
1010	Na	--	4-Cl	
1011	Na	--	4-Cl	
1012	Na	--	4-Cl	
1013	Na	--	4-Cl	
1014	Na	--	4-Cl	
1015	Na	--	3-Cl	
1016	Na	--	4-CF ₃	
1017	CH ₃	--	4-Cl	
1018	Na	--	3-CH ₃	
1019	Na	<i>a</i> -F	4-Cl	
1020	Na	--	3,5-Cl	
















Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1021	Na	--	3,4-Cl	
1022	CH ₃	--	3,4-Cl	
1023	Na	--	3-OCH ₃	
1024	Na	--	3,4-CH ₃	
1025	Na	--	3,4-Cl	
1026	Na	--	3,4-F	
1027	Na	--	3,4-Br	
1028	Na	--	3,4-Cl	
1029	Na	--	3-F, 4-Cl	
1030	Na	--	3-Cl, 4-F	
1031	Na	--	3-CF ₃	
1032	Na	--	3-Cl	
1033	Na	--	3,4-Cl	













Cpd #	R ^{4A}	R ¹	-R ⁵	-R ³
1034	Na	--	3,4-Cl	
1035	Na	--	3,4-Cl	
1036	Na	--	3,4-Cl	
1037	Na	<i>b</i> -CH ₃	3,4-Cl	
1038	Na	--	3,4-Cl	
1039	Na	--	4-I	
1040	Na	--	3,4-Cl	
1041	Na	<i>α</i> -CH ₃	3,4-Cl	
1042	Na	<i>α</i> -CH ₃	3,4-Cl	
1043	Na	--	3,4-Cl	
1044	Na	--	3-Cl	
1045	Na	--	3-F, 4-CF ₃	
1046	Na	--	3,4-Cl	













Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1047	Na	--	3,4-Cl	
1048	Na	<i>d</i> -F	3,4-Cl	
1049	Na	--	3,4-Cl	
1050	Na	--	3,4-Cl	
1051	Na	<i>a</i> -F	3,4-Cl	
1052	Na	--	3,4-Cl	
1053	Na	--	3,4-Cl	
1054	Na	--	3,4-Cl	
1055	Na	--	3,4-Cl	
1056	Na	--	3,4-CH ₃	
1057	Na	--	3,4-Cl	
1058	Na	--	3,4-Cl	
1059	Na	--	3,4-F	
1060	Na	--	3,4-Cl	













Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1061	Na	--	3,4-F	
1062	Na	--	3,4-F	
1063	Na	--	3,4-Cl	
1064	Na	--	3,4-F	
1065	Na	--	3,4-Cl	
1066	Na	--	3,4-Cl	
1067	Na	--	3-F, 4-CF ₃	
1068	Na	--	3,4-F	
1069	Na	<i>b</i> -Br	3,4-Cl	
1070	Na	--	3,4-Cl	
1071	Na	--	3,4-CH ₃	
1072	Na	--	3,4-Br	
1073	Na	--	3,4-F	
1074	Na	--	3,4-Br	
1075	Na	--	3,4-Br	








Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1076	Na	--	3,4-Br	
1077	Na	--	3,4-Cl	
1078	Na	--	3,4-Br	
1079	Na	--	3,4-Br	
1080	Na	--	3-CN	
1081	Na	--	3,4-Br	
1082	Na	--	3,4-Cl	
1083	Na	--	3,4-F	
1084	Na	--	3,4-Br	
1085	Na	--	3-CN	
1086	Na	--	3,4-Br	
1087	Na	--		
1088	Na	--	3,4-Br	 stereochemistry undetermined
1089	Na	--	3,4-Br	 stereochemistry

Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
				undetermined
1090	Na		3,4-Cl	
1091	Na		3,4-Cl	
1092	Na	--	3,4-Br	
1093	Na	--	3-Cl, 4-F	
1094	Na	--	3-Cl, 4-F	
1095	Na		3,4-Cl	
1096	Na	--	3,4-Cl	
1097	Na	--	3,4-Br	
1098	Na	--	3,4-Cl	
1099	Na	--	3,4-Br	
1100	Na	--	3,4-Cl	
1101	Na	--	3,4-Cl	


Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1102	Na	--	3,4-Br	
1103	Na	--	3,4-Br	
1104	Na	--	3,4-Cl	
1105	Na	--	3,4-Br	
1106	Na	<i>b</i> -F	3,4-Cl	
1107	Na	<i>c</i> -F	3,4-Cl	
1108	Na	--	3,4-Cl	
1109	Na	--	3,4-Br	
1110	Na	--	3,4-Br	
1111	Na	--	3,4-Cl	
1112	Na	--	3,4-Cl	
1113	Na	--	3,4-Br	

Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1114	Na	<i>o</i> -Cl	3,4-Cl	
1115	Na	--	3-Cl, 4-F	
1116	Na	<i>b</i> -Cl	3,4-Cl	
1117	Na	--	3,4-Cl	
1118	Na	--	3,4-Br	
1119	Na	--	3,4-Br	
1120	Na	--	3-Cl, 4-F	
1121	Na	--	3-Cl, 4-F	
1122	Na	--	3-Cl, 4-F	
1123	Na	--	3,4-Cl	
1124	Na	--	3,4-Cl	
1125	Na	--	3,4-Cl	

Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1126	Na	--	3,4-Cl	
1127	Na	--	3,4-Cl	
1128	Na	--	3,4-Cl	
1129	Na	<i>o</i> -OMe	3,4-Cl	
1130	Na	<i>b</i> -OMe	3,4-Cl	
1131	Na	--	3-Cl, 4-F	
1132	Na	--	3,4-F	
1133	Na	--	3,4-Cl	
1134	Na	--	3,4-Br	
1135	Na	--	3,4-Cl	
1136	Na	--	3,4-Cl	
1137	Na	--	3,4-Cl	











Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
1138	Na	--	3,4-Cl	
1139	Na	--	3,4-Cl	
1140	Na	--	3,4-Cl	
1141	Na	--	3-NHC(O) (CH ₂) ₃ C H ₃ , 4-Cl	
1142	Na	--	3,5-Cl	
1143	Na	b-F	3,4-Br	
1144	Na	c-F	3,4-Br	

26. A compound selected from the group consisting of: compounds having the following formula:




wherein R^{4A} , R^1 , R^5 , and R^3 are as defined as follows:

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$
A1001	Na	--	3,4-Br	 stereochemistry undetermined
A1002	Na	--	3,4-Br	 stereochemistry undetermined
A1003	Na	mixture <i>b</i> -Me & <i>c</i> -Me	3,4-Cl	 stereochemistry undetermined
A1004	Na	<i>b</i> -Me	3,4-Cl	 stereochemistry undetermined
A1005	Na	<i>c</i> -Me	3,4-Cl	 stereochemistry undetermined
A1006	Na	mixture <i>b</i> -Me & <i>c</i> -Me	3,4-Cl	 stereochemistry undetermined








Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
A1007	Na	<i>b</i> -Me	3,4-Cl	 stereochemistry undetermined
A1008	Na	<i>c</i> -Me	3,4-Cl	 stereochemistry undetermined
A1009	Na	mixture <i>b</i> -Me & <i>c</i> -Me	3,4-Br	 stereochemistry undetermined
A1010	Na	<i>b</i> -Me	3,4-Br	 stereochemistry undetermined
A1011	Na	<i>c</i> -Me	3,4-Br	 stereochemistry undetermined
A1012	Na	--	3,4-Br	 stereochemistry undetermined
A1013	Na	--	3,4-Br	 stereochemistry undetermined
A1014	Na	<i>c</i> -Me	3,4-Br	 stereochemistry undetermined
A1015	Na	<i>b</i> -F, <i>c</i> -Me	3,4-Br	 stereochemistry undetermined
A1016	Na	<i>b</i> -Me, <i>c</i> -F	3,4-Br	 stereochemistry undetermined


; and

27. A compound selected from the group consisting of: compounds having the following formula:




wherein R^1 , R^5 , and R^3 are as defined as follows:




Cpd #	R^1	R^5	R^3	
B1001	b-Me, c-Me (mixture)	3,4-Br		;
B1002	b-Me	3,4-Br		;
B1003	c-Me	3,4-Br		;
B1004	b-Me	3,4-Br		;
B1005	c-Me	3,4-Br		;
B1006	b-Me	3,4-Br		;
B1007	c-Me	3,4-Br		; and

B1008	b-F, c-Me	3,4-Br	
-------	-----------	--------	--


28. A compound selected from the group consisting of: compounds having the following formula:







wherein R^5 and R^3 are as defined as follows:

Cpd #	R^5	R^3
C1001	3,4-Cl	
C1002	3,4-Br	
C1003	3,4-Br	


29. A compound selected from the group consisting of: compounds having the following formula:







wherein R^5 and R^3 are defined as follows:















Cpd #	R ⁵	R ³	
D1001	3,4-Cl		;
D1002	3,4-Br		;
D1003	3,4-Br		; and
D1004	3,4-Br		.





30. A compound selected from the group consisting of: compounds having the following formula:




wherein R⁵ and R³ are as defined as follows:

Cpd #	--R ⁵	---R ³	
2002	4-Cl		;
2003	4-Cl		;
2004	4-Cl		;
2005	3-Cl		;









Cpd #	--R ⁵	---R ³
2006	4-Cl	
2007	4-Cl	
2008	4-CF ₃	
2009	4-Cl	
2010	4-Cl	
2011	4-Cl	
2012	4-Cl	
2013	3,4-Cl	
2014	3-CH ₃	
2015	4-Cl	
2016	3,4-Cl	
2017	4-I	
2018	3,4-Cl	
2019	3,4-Cl	

























Cpd #	--R ⁵	--R ³	
2020	4-OH, 5-Cl		;
2021	3,4-Cl		;
2022	3,4-Cl		; and
2023	3,4-Br		.

31. A compound selected from the group consisting of: compounds having the following formula:




wherein R¹, Y, and R³ are as defined as follows:

Cpd #	R ¹	--Y	--R ³	
3001	--			;
3002	--			;
3003	--			;
3004	--			;

Cpd #	R ¹	--Y	--R ³
3006	--		
3007	--		
3008	--		
3009	--		
3100	--		
3011	--		
3012	--		
3013	c-Me		
3014	--		
3015	--		
3016	b-F		
3017	c-F		

; and

32. A compound selected from the group consisting of: compounds having the following formula:




wherein Y and R³ are as defined as follows:

Cpd #	--Y	--R ³
4001		
4002		
4003		
4004		
4005		
4006		
4007		
4008		

Cpd #	--Y	--R ³
4009		
4010		
4011		
4012		

; and


33. A compound having the following formula:




wherein R⁵ and R³ are as defined as follows:

Cpd #	--R ⁵	--R ³
5001	3,4-Cl	


34. A compound having the following formula:




wherein R⁵ and R³ are as defined as follows:

Cpd #	--R ⁵	--R ³
6001	3,4-Cl	


35. A compound having the following formula:



wherein X, R^{4A}, R⁵ and R³ are as defined as follows:


Cpd #	R ^{4A}	--R ⁵	--R ³
7001	OCH ₃	3,4-Cl	

36. A compound having the following formula:




wherein R⁵ and R³ are as defined as follows:



Cpd #	--R ⁵	--R ³
-------	------------------	------------------

8001	3,4-Cl	
------	--------	---


37. A compound having the following formula:





wherein W, R⁵ and R³ are as defined as follows:

Cpd #	W	--R ⁵	--R ³
9001		3,4-Cl	

38. A compound having the following formula:



wherein Y and R³ are as defined as follows:

Cpd #	--Y	--R ³
10,001		

39. A pharmaceutical composition comprising an anti-papillomavirus virally

effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.


40. A method for treating a papillomavirus viral infection in a mammal by administering to the mammal an anti-papilloma virus virally effective amount of the compound of formula (I), according to claim 1 without the provisos indicated in claim 1, or a therapeutically acceptable salt or ester thereof, or a pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 without the provisos indicated in claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

41. A method for inhibiting the replication of papillomavirus by exposing the virus to an amount of the compounds of formula (I), according to claim 1 without the provisos indicated in claim 1, inhibiting the papilloma virus E1-E2-DNA complex, or a therapeutically acceptable salt or ester thereof, or a composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 without the provisos indicated in claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

42. A method of preventing perinatal transmission of HPV from mother to baby, by administering a compound of formula (I), according to claim 1, without the provisos indicated in claim 1, to the mother prior to giving birth.

43. An intermediate compound of formula vi:


118



vi

wherein R^3 and Y are as defined in claim 1, with the provisos indicated in claim 1.


44. An intermediate compound of formula xx:



xx

wherein R^3 , R^4 , and Y are as defined in claim 1, with the provisos indicated in claim 1.


45. An intermediate compound of formula xxvi:



xxvi

wherein R^1 , Y , and R^3 are as defined in claim 1, without the provisos indicated in claim 1.


46. An intermediate compound of formula xxxii:



xxxii

wherein R^1 , R^3 and Y are as defined in claim 1, without the provisos indicated in claim 1.


47. A process for producing a compound of formula I',




wherein X , R^1 , W , Y , R^3 , and R^4 are as defined in claim 1, with the provisos indicated in claim 1,

comprising:

a) hydrolyzing, in a mixture of aqueous base and a co-solvent, either intermediate compound vi or intermediate compound xx



vi



xx

to produce compounds of formula I', wherein R^3 , R^4 , and Y are as defined in claim 1.

48. A process for producing compounds of formula I', according to claim 47, comprising:


b) acidifying said mixture with aqueous acid so as to produce compounds of formula I'.

49. A process, according to claim 48, for producing compounds of formula I', comprising:

c) treating the product from b) with diazomethane.


50. A process, according to claim 47, for producing compounds of formula I', comprising:

a) reducing, in a mixture of a hydride source and an aprotic solvent, intermediate vi:



vi

to produce a mixture of monohydroxy intermediates xiv and xv:




xiv and xv

wherein Y and R³ are as defined in claim 1.

51. A process for producing compounds of formula I', according to claim 50, comprising:

- a) hydrolyzing, in a mixture of aqueous base and a co-solvent, intermediates xiv and xv, to produce compounds of formula I'.


52. A process for producing compounds of formula I'',



wherein **X** and **W** together form a carbonyl group, **R⁴** is a carboxylic acid or an ester, and **R¹**, **Y**, and **R³** are as defined in claim 1, without the provisos indicated in claim 1,

comprising:


- a) hydrolyzing, in a mixture of aqueous base and a co-solvent, intermediate compound xxvi,



xxvi

so as to produce compounds of formula I'', wherein **R¹**, **Y**, and **R³** are as defined in claim 1.


53. A process for producing compounds of formula I''', comprising:



wherein **X** and **W** together form a carbonyl group, **R⁴** is a carboxylic acid or an ester, and **R¹**, **Y**, and **R³** are as defined in claim 1, without the provisos indicated in claim 1,

comprising:

- a) hydrolyzing, in a mixture of aqueous base and a co-solvent, intermediate compound xxxii



xxxii

so as to produce compounds of formula I''', wherein **R¹**, **Y**, and **R³** are as defined in claim 1.